Verispan acquired by data rival SDI

Verispan has been bought by rival healthcare analytics firm SDI for an undisclosed price.

A privately owned firm based in Plymouth Meeting, PA, SDI offers similar patient-level data analytics services, but where Verispan's syndicated offerings have formed the crux of its business, SDI has focused more on custom programs. 

SDI's John Ross, VP client services, said the company anticipates minimal redundancies initially. “The services of both firms are pretty complementary,” he said. “The only overlap is in the patient level data space, and within that, only on the custom offerings. That's one of the aspects of the deal that made it very attractive for both parties.”

The organization will be known as SDI, though select offerings may retain the Verispan brand, Ross said. It will boast a staff of 700, with Verispan's 500 employees remaining in their Yardley, PA, offices, and will be led by CEO Andrew Kress, who was president of SDI. Verispan CEO Wayne Yetter is leaving the company after a transition period. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.